Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune Inc (ALT) is a clinical-stage biopharmaceutical company pioneering peptide-based therapeutics for obesity, metabolic disorders, and liver diseases. This page serves as the definitive source for verified news and press releases directly from the company and trusted financial publications.
Investors and researchers will find timely updates on clinical trial progress, including developments for pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate. Track regulatory milestones, partnership announcements, and strategic initiatives that shape Altimmune’s research pipeline.
Our curated news feed includes earnings reports, scientific presentations, and manufacturing updates, providing a holistic view of the company’s trajectory. All content is rigorously vetted to ensure alignment with financial reporting standards and clinical accuracy.
Bookmark this page for efficient access to Altimmune’s latest material events. Check regularly for updates on pivotal studies in metabolic-associated steatohepatitis (MASH) and obesity therapeutics, ensuring you stay informed on developments impacting this innovative biopharma leader.
Altimmune's AdCOVID, a single-dose intranasal COVID-19 vaccine, shows promising preclinical results. The comprehensive evaluation highlights AdCOVID's ability to stimulate serum neutralizing antibodies, T cell responses, and mucosal immunity in the respiratory tract. In studies with mice, AdCOVID demonstrated a median neutralization titer of 1:563, exceeding FDA's convalescent plasma standard. The company plans to file an IND and begin a Phase 1 trial in Q4 2020. AdCOVID's advantages include easy storage, broad immune activation, and potential for self-administration.
Altimmune, Inc. (Nasdaq: ALT) announced a preclinical data presentation on ALT-801, a GLP-1/glucagon receptor dual agonist, targeting NASH at the Digital International Liver Congress™ 2020. The presentation highlighted ALT-801’s superior efficacy compared to semaglutide in reducing body weight, liver fat, and fibrosis markers in a preclinical mouse model. The company is preparing to start its first human Phase 1 trial in Australia in Q4 2020, with results anticipated in spring 2021.
Altimmune, Inc. (Nasdaq: ALT) reported promising results from preclinical studies of its intranasal COVID-19 vaccine candidate, AdCOVID. The research demonstrated significant stimulation of CD4+ and CD8+ T cell responses in the lungs of mice, with a strong bias towards CD8+ T cells within 10 days post-vaccination. AdCOVID showed a 29-fold increase in mucosal IgA antibodies specific to the spike protein. The company is on track to start a Phase 1 safety and immunogenicity study in Q4 2020. The vaccine's intranasal administration could facilitate rapid distribution without cold-chain logistics.
Altimmune, Inc. (Nasdaq: ALT) announced it will report its financial results for Q2 2020 before the market opens on August 12, 2020, and will host a conference call at 8:30 am ET. The company is focused on developing intranasal vaccines and immune modulating therapies, including those for COVID-19 and liver diseases. Notable products in their pipeline include AdCOVID™, NasoShield™, and ALT-801. Investors can access the conference call via the provided webcast link.
Altimmune, Inc. (Nasdaq: ALT) has partnered with Vigene Biosciences to manufacture its intranasal COVID-19 vaccine, AdCOVID. Following encouraging pre-clinical results, Altimmune plans to initiate a Phase 1 clinical trial in Q4 2020. The collaboration aims to produce at least 100 million doses of AdCOVID in 2021. AdCOVID is designed to activate both mucosal and systemic immunity, potentially offering effective defense against SARS-CoV-2 infection and spread. The partnership leverages Vigene's viral vector expertise and state-of-the-art manufacturing capabilities.
Altimmune, Inc. (Nasdaq: ALT) announced a public offering of 4,119,564 shares of common stock and pre-funded warrants for 1,630,436 shares, raising approximately $132.2 million. The offering price was $23.00 per share and $22.9999 per warrant. Proceeds will be utilized for scaling manufacturing, advancing clinical trials of AdCOVID, and continuing the development of ALT-801 for NASH. Jefferies, Evercore ISI, and Piper Sandler managed the offering, with Roth Capital Partners as co-manager. The securities were offered under a Form S-3 shelf registration.
Altimmune, Inc. (Nasdaq: ALT) announced a public offering of 3,369,564 shares of its common stock at $23.00 per share, along with pre-funded warrants to purchase 1,630,436 shares at $22.999 each. The offering is expected to generate gross proceeds of $115 million, closing around July 16, 2020. Funds will support manufacturing and clinical trials for AdCOVID, an intranasal COVID-19 vaccine, and ALT-801, for treating NASH. The underwriters have a 30-day option to purchase an additional 750,000 shares.
Altimmune, Inc. (Nasdaq: ALT) announced a planned underwritten public offering of common stock, which may include pre-funded warrants for certain investors. The underwriters will have an option to purchase an additional 15% of shares. Proceeds will be used for general corporate purposes, including scaling up manufacturing for its COVID vaccine candidate AdCOVID and advancing clinical trials for ALT-801, targeting non-alcoholic steatohepatitis. The offering is subject to market conditions and is being managed by Jefferies, Evercore ISI, and Piper Sandler.
Altimmune, Inc. (Nasdaq: ALT) announced promising results from preclinical studies of its intranasal COVID-19 vaccine candidate, AdCOVID. Conducted with UAB, the studies indicated strong serum neutralizing activity and mucosal immunity. AdCOVID demonstrated significant antibodies in mice, reaching serum IgG concentrations over 800 µg/mL within 14 days. The vaccine will progress to Phase 1 trials in Q4 2020. Notably, its intranasal delivery could enhance rapid administration and distribution without cold-chain requirements.
